Sight Sciences Inc (SGHT)

Currency in USD
10.75
-0.26(-2.36%)
Closed·
10.750.00(0.00%)
·
SGHT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
10.5310.97
52 wk Range
3.3811.16
Key Statistics
Prev. Close
10.75
Open
10.97
Day's Range
10.53-10.97
52 wk Range
3.38-11.16
Volume
466.95K
Average Volume (3m)
317.06K
1-Year Change
52.6989%
Book Value / Share
0.89
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SGHT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
11.33
Upside
+5.43%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Sight Sciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

6 Buy
2 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 11.33
(+5.43% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Lake Street
Buy14.00+30.23%12.00MaintainNov 05, 2026
Piper Sandler
Buy12.00+11.63%9.00MaintainNov 05, 2026
Stifel
Buy10.00-6.98%8.00MaintainNov 05, 2026
H.C. Wainwright
Buy14.00+30.23%-New CoverageOct 15, 2026
UBS
Buy7.00-34.88%-New CoverageJul 28, 2026

Sight Sciences Inc Earnings Call Summary for Q2/2026

  • Q2 revenue rose 20% YoY to $23.4M, fastest growth since 2023; net loss narrowed to $4.4M from $11.9M; shares fell 5.59% after hours.
  • Gross margin expanded to 91% from 85%, aided by pricing gains and tariff refunds; interventional dry eye revenue nearly doubled to $2.7M.
  • Full-year 2026 revenue guidance raised to $88M-$92M from $83M-$89M; Q3 growth expected in mid-to-high teens year-over-year.
  • Operating expenses fell 11% to $25.3M; cash used in Q2 dropped 81% to $1.4M, signaling progress toward cash flow breakeven.
  • OMNI Ultra glaucoma device not included in 2026 guidance; broader launch planned for Q4 following AAO conference.
Last Updated: 05/08/2026, 22:40
Read Full Transcript

Earnings

Latest Release
Nov 04, 2026
EPS / Forecast
-0.64 / -0.16
Revenue / Forecast
24.92M / 23.55M
EPS Revisions
Last 90 days

SGHT Income Statement

Compare SGHT to Peers and Sector

Metrics to compare
SGHT
Peers
Sector
Relationship
P/E Ratio
−21.0x−2.1x−0.2x
PEG Ratio
−0.52−0.160.00
Price/Book
12.2x2.6x2.6x
Price / LTM Sales
6.8x3.3x2.8x
Upside (Analyst Target)
5.4%121.8%60.9%
Fair Value Upside
Unlock6.0%9.5%Unlock

Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists. It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
6.19M11.24%68.19M
Other Institutional Investors
25.98M47.16%286.05M
Public Companies & Retail Investors
22.91M41.59%252.27M
Total
55.09M100.00%606.52M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Allegro Investment Fund, L.P.9.23%5,086,92056,007
Allegro Investment Inc.9.23%5,086,92056,007

People Also Watch

154.00
ANF
+0.78%
20.810
DHT
+1.22%
6.5100
BFLY
-2.40%
17.65
RCEL
+3.10%
108.06
KOD
+0.90%

FAQ

What Is the Sight Sciences (SGHT) Stock Price Today?

The Sight Sciences stock price today is 10.75 USD.

What Stock Exchange Does Sight Sciences Trade On?

Sight Sciences is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Sight Sciences?

The stock symbol for Sight Sciences is "SGHT."

What Is the Sight Sciences Market Cap?

As of today, Sight Sciences market cap is 597.47M USD.

What Is Sight Sciences's Earnings Per Share (TTM)?

The Sight Sciences EPS (TTM) is -0.52.

When Is the Next Sight Sciences Earnings Date?

Sight Sciences will release its next earnings report on Mar 10, 2027.

From a Technical Analysis Perspective, Is SGHT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Sight Sciences Stock Split?

Sight Sciences has split 0 times.

How Many Employees Does Sight Sciences Have?

Sight Sciences has 186 employees.

What is the current trading status of Sight Sciences (SGHT)?

As of Nov 11, 2026, Sight Sciences (SGHT) is trading at a price of 10.75 USD, with a previous close of 10.75 USD. The stock has fluctuated within a day range of 10.53 USD to 10.97 USD, while its 52-week range spans from 3.38 USD to 11.16 USD.

What Is Sight Sciences (SGHT) Price Target According to Analysts?

The average 12-month price target for Sight Sciences is 11.33 USD, with a high estimate of 14 USD and a low estimate of 8 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +5.43% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.